robatumumab + irinotecan + folinic acid + 5-fluorouracil + cetuximab

A five-drug combination therapy consisting of **robatumumab** (a monoclonal antibody against IGF-1R), **irinotecan** (a topoisomerase I inhibitor), **folinic acid** (leucovorin, a folate analog used to enhance fluorouracil efficacy), **5-fluorouracil** (5-FU, an antimetabolite acting as a thymidylate synthase inhibitor), and **cetuximab** (a monoclonal antibody targeting EGFR). - **Robatumumab** is an anti-IGF-1R human monoclonal antibody, developed for oncologic indications, working by inhibiting signaling that promotes cell survival and proliferation. - **Irinotecan** inhibits topoisomerase I, leading to DNA damage and cell death in rapidly dividing cells. - **Folinic acid** stabilizes the binding of 5-fluorouracil to thymidylate synthase, enhancing its cytotoxic effect. - **5-fluorouracil** is a pyrimidine analog that irreversibly inhibits thymidylate synthase, impairing DNA synthesis in cancer cells. - **Cetuximab** binds to the extracellular domain of EGFR, blocking ligand-induced activation and downstream signaling that controls cell proliferation and survival; it also induces antibody-dependent cellular cytotoxicity. The combination aims to block complementary growth, survival, and repair pathways in metastatic colorectal cancer and other solid tumors, especially in patients with KRAS wild-type tumors for the EGFR-targeted component[1][3][4].